Henry J. Haringsma
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Radiopharmaceutical Chemistry and Applications, Cytokine Signaling Pathways and Interactions, Heat shock proteins research, PARP inhibition in cancer therapy
Most-Cited Works
- → Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients(2016)655 cited
- → Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC(2013)624 cited
- → Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer(2018)281 cited
- → Correction: Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients(2016)245 cited
- → Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy(2007)235 cited
- → Inactivation of Capicua drives cancer metastasis(2016)166 cited
- → Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance(2008)156 cited
- → The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272(2007)110 cited
- → Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5′-terminal phosphorylation both in vitro and in vivo(2009)83 cited
- → Nucleobase and Ribose Modifications Control Immunostimulation by a MicroRNA-122-mimetic RNA(2011)74 cited